Form 4: Bolt Biotherapeutics Director Acquires Stock Options

Jakob Dupont, a director at Bolt Biotherapeutics, acquired stock options for 66,984 shares of common stock on September 3, 2024.

Summary

• On September 3, 2024, Jakob Dupont, a director of Bolt Biotherapeutics, acquired stock options.
• These options are for 50,000 shares and 16,984 shares of Bolt Biotherapeutics common stock.
• The exercise price for both options is $0.6798.
• The options expire on September 2, 2034.
• The 50,000 share option vests monthly over 36 months, contingent on continuous service, but vests fully upon a change in control.
• The 16,984 share option vests fully on the date immediately preceding the next annual stockholder meeting, provided Dupont is still a director, and also vests fully upon a change in control.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. The vesting schedule implies a positive outlook, but it's not overtly bullish.

Positives

• The acquisition of stock options by a director signals confidence in the company's future.
• The vesting schedules incentivize continued service and alignment with shareholder interests.

Future Outlook

The vesting schedules suggest a continued commitment from the director to the company's success.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in company stock.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign of alignment between management and shareholder interests.

Key Dates